Microplasmin receives orphan drug protection

Article

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Recent Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
National Academies of Sciences, Engineering, and Medicine publishes new report focusing on myopia

National Academies of Sciences, Engineering, and Medicine publishes new report focusing on myopia

Article
ROP: Treating and preventing blindness in preterm babies

ROP: Treating and preventing blindness in preterm babies

Podcast
Prevent Blindness kicks off World Sight Day activities with congressional briefing on Capitol Hill, partnerships and vision screening events nationwide

Prevent Blindness kicks off World Sight Day activities with congressional briefing on Capitol Hill, partnerships and vision screening events nationwide

Article
Managing a changing landscape of IRD pediatric cases

Managing a changing landscape of IRD pediatric cases

Podcast
Isolated cranial sixth nerve palsy after COVID-19

Isolated cranial sixth nerve palsy after COVID-19

Article
The American Academy of Ophthalmology, Research to Prevent Blindness announce recipients of RPB/AAO Award for IRIS Registry Research

The American Academy of Ophthalmology, Research to Prevent Blindness announce recipients of RPB/AAO Award for IRIS Registry Research

Article
© 2024 MJH Life Sciences

All rights reserved.